Publications in collaboration with researchers from Fudan University (2)

2023

  1. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10415, pp. 1835-1847

  2. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 401, Núm. 10391, pp. 1853-1865